HSBC Reiterates “€150.00” Price Target for Sartorius (FRA:SRT3)

Share on StockTwits

HSBC set a €150.00 ($174.42) price target on Sartorius (FRA:SRT3) in a research report report published on Friday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Several other research analysts have also weighed in on the stock. Deutsche Bank increased their target price on shares of Bed Bath & Beyond from $15.00 to $19.00 and gave the stock a hold rating in a research note on Thursday, April 11th. Nord/LB set a €115.00 ($133.72) price objective on shares of Sartorius and gave the company a sell rating in a research note on Tuesday, April 23rd. UBS Group set a $54.00 price objective on shares of Westlake Chemical and gave the company a sell rating in a research note on Tuesday, July 2nd. Berenberg Bank reissued a buy rating and issued a GBX 360 ($4.70) price objective on shares of in a research note on Thursday, June 6th. Finally, Hauck & Aufhaeuser set a €55.00 ($63.95) price objective on shares of Cancom and gave the company a buy rating in a research note on Thursday, April 4th. Five equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the company. Sartorius presently has an average rating of Sell and an average price target of €137.94 ($160.40).

Shares of SRT3 stock opened at €184.60 ($214.65) on Friday. The stock’s 50-day moving average is €178.22. Sartorius has a 1-year low of €71.00 ($82.56) and a 1-year high of €124.70 ($145.00).

About Sartorius

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

Read More: Do equity income investments outperform growth and income investments?

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.